With the potential for a hard-no-deal Brexit becoming closer to reality with each passing day, the question of what this means for healthcare and pharma is ever more prominent. To gain some ...

Pharma must embrace the opportunity to shape the UK’s political agenda in its favour. Saving the jewel in the crown of ‘UKplc’: Brexit's impact on pharma | pharmaphorum Skip to main content ...

The Brexit impact on pharma industry will be around Rs 400-500 crore, with companies facing issues in regulatory and approval process going forward. Brexit to have an impact of around Rs 400-500 ...

Sameer Walia, Managing Director, The Smart Cube examines the potential implications of Brexit on the overall pharma industry in India In early 2016, multiple reports from different research houses ...

[9] BREXIT EFPIA survey results of 8 November 2017, European Federation of Pharmaceutical Industries and Associations. [10] No. 4 of EMA Guidance. [11] No. 4c of EMA Guidance.

A new poll of the pharma industry has found that 48% believe ‘No Brexit’ is the best option – but a quarter believes a ‘no deal’ Brexit is the most likely outcome. Pharma market analysts GlobalData ...

This past Friday, GEN covered the news that the U.K. had voted to leave the European Union: “Keeping a Stiff Upper Lip Despite Brexit.” GEN subsequently asked a number of biotech scientists ...

In January, the prime minister, Theresa May, warned the EU that “no deal for Britain is better than a bad deal” when it comes to Brexit. Although her government is now edging away from that position, ...

The impact of Brexit on the pharmaceutical industry has yet to be determined, but some fear that Brexit will cause the UK to lag behind in the biosimilar sphere in particular.

Brexit may affect the cost of medicines and hit UK pharmaceutical investment, a Commons committee head has warned. Rachel Reeves, who chairs the Business, Energy and Industrial Strategy (BEIS ...

Brexit impact on Indian pharma is going to be minimal, as the UK and the EU account for less than 13 per cent of the overall Indian pharma revenues.